Benjamin F. Edwards & Company Inc. reduced its position in shares of McKesson Co. (NYSE:MCK) by 3.5% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,436 shares of the company’s stock after selling 123 shares during the quarter. Benjamin F. Edwards & Company Inc.’s holdings in McKesson were worth $465,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Whittier Trust Co. increased its holdings in McKesson by 1.6% during the 1st quarter. Whittier Trust Co. now owns 18,217 shares of the company’s stock worth $2,464,000 after purchasing an additional 291 shares during the period. Chicago Equity Partners LLC increased its holdings in McKesson by 12.3% during the 4th quarter. Chicago Equity Partners LLC now owns 5,665 shares of the company’s stock worth $784,000 after purchasing an additional 620 shares during the period. Strs Ohio increased its holdings in McKesson by 1.3% during the 4th quarter. Strs Ohio now owns 215,511 shares of the company’s stock worth $29,809,000 after purchasing an additional 2,699 shares during the period. Andra AP fonden increased its holdings in McKesson by 4.0% during the 4th quarter. Andra AP fonden now owns 56,800 shares of the company’s stock worth $7,857,000 after purchasing an additional 2,200 shares during the period. Finally, AE Wealth Management LLC increased its holdings in McKesson by 1.7% during the 4th quarter. AE Wealth Management LLC now owns 10,834 shares of the company’s stock worth $1,499,000 after purchasing an additional 182 shares during the period. Institutional investors own 88.18% of the company’s stock.

Shares of MCK stock opened at $136.45 on Friday. The stock has a market cap of $22.49 billion, a PE ratio of -27.90, a price-to-earnings-growth ratio of 1.49 and a beta of 0.82. The business has a 50-day simple moving average of $134.44 and a 200-day simple moving average of $142.87. The company has a quick ratio of 0.56, a current ratio of 0.98 and a debt-to-equity ratio of 1.33. McKesson Co. has a 52-week low of $112.60 and a 52-week high of $172.18.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 1st. Stockholders of record on Monday, June 1st will be issued a $0.41 dividend. The ex-dividend date of this dividend is Friday, May 29th. This represents a $1.64 annualized dividend and a dividend yield of 1.20%. McKesson’s dividend payout ratio (DPR) is presently 12.09%.

In other news, CEO Brian S. Tyler sold 4,063 shares of the business’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $135.00, for a total value of $548,505.00. Following the completion of the transaction, the chief executive officer now owns 16,255 shares of the company’s stock, valued at approximately $2,194,425. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last three months, insiders sold 8,187 shares of company stock valued at $1,064,057. Insiders own 0.88% of the company’s stock.

Several research analysts have commented on the company. Morgan Stanley reduced their price objective on McKesson from $182.00 to $150.00 and set an “overweight” rating on the stock in a report on Friday, March 27th. Guggenheim upgraded McKesson from a “neutral” rating to a “buy” rating in a report on Friday, March 13th. Robert W. Baird raised McKesson from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $164.00 to $197.00 in a research report on Friday, February 7th. UBS Group raised McKesson from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $151.00 to $160.00 in a research report on Friday. Finally, JPMorgan Chase & Co. raised their price objective on McKesson from $186.00 to $187.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 18th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and seven have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $163.82.

McKesson Profile

McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.

Featured Story: What is the Current Ratio?

Institutional Ownership by Quarter for McKesson (NYSE:MCK)

Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.